A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
Phase 4
764
about 1.7 years
0.5+
6 sites in GA, LA, MS +2
What this study is about
This trial is testing a new type of vaccine against COVID-19. The goal is to see how well this vaccine works and if it's safe for adults and children.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive mRNA-1273 Variant-containing Formulation
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Secondary: mRNA-1273.167, mRNA-1273.712, mRNA-1273.251, and mRNA-1273.261: Number of Participants with Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Study Withdrawal, and AEs of Special Interest, mRNA-1273.251 and mRNA-1273.261: Number of Participants with Unsolicited AEs
Infectious